J Frontier, the Tokyo-listed operator of the online medical consultation and medication-guidance app SOKUYAKU, has rewritten how it charges the clinics and pharmacies on its network. Patients using the app still pay what they paid before. The partners on the other side of the platform do not.
Until now, SOKUYAKU's roughly 4,000 partner clinics paid a single usage-based fee tied to how much they used the platform, and its roughly 20,000 partner pharmacies paid nothing at all. Under the new schedule, clinics keep that usage fee and add a new sign-up fee and a new monthly fee. Pharmacies, which previously had no charge, now get all three: a sign-up fee, a monthly fee, and a new usage-based fee tied to how many prescriptions they fill through the app.
| Partner type | Fee item | Before | After |
|---|---|---|---|
| Clinics (~4,000) | Sign-up fee | None | New |
| Clinics (~4,000) | Monthly fee | None | New |
| Clinics (~4,000) | Usage fee | Existing | Continues, unchanged |
| Pharmacies (~20,000) | Sign-up fee | None | New |
| Pharmacies (~20,000) | Monthly fee | None | New |
| Pharmacies (~20,000) | Usage fee | None | New |
J Frontier frames this as turning a single revenue layer per contract into three. The new terms already apply to new partners signing up, and the company is rolling them out to existing clinics and pharmacies gradually rather than all at once.
The company's pitch to investors is about margin, not just revenue. It says the added billing requires little to no extra cost, because the customer-support and system upgrades behind the new pricing were already funded in its existing cost plan. That means, in J Frontier's own words, revenue growth from the change should translate almost directly into operating profit growth.
The numbers attached to that claim are specific: J Frontier's operating profit guidance for the fiscal year ending May 2027 is ¥1.05bn, up from ¥312mn the prior year, a rise the company describes as 236.2%. The fee revision is one of the drivers already folded into that forecast, disclosed on July 15, 2026, and this supplementary filing on July 21 exists specifically because investors asked why the SOKUYAKU business is growing.
J Frontier also points to two policy tailwinds behind the platform's growth: Japan's disaster-prevention and land-resilience push, and deregulation under revised medical and pharmaceutical laws. It shows an indexed sales chart for SOKUYAKU running from 100 in the year to May 2024 up to 150 in the year to May 2026, with the years to May 2028 through 2030 shown only as an illustrative growth image rather than firm figures.
What the filing does not settle is timing. J Frontier has not disclosed what share of its 24,000 combined partners have moved onto the new fee schedule so far, only that the rollout to existing accounts is proceeding "in stages." How quickly that stage-by-stage rollout completes will determine how fast the promised profit lift actually shows up.